Rapid diagnostic HCV antibody assays

Antiviral Therapy

Volumn 17, Issue 7 PARTB, 2012, Pages 1409-1413

  Smith, Bryce D ^a   Jewett, Amy ^a   Drobeniuc, Jan ^a   Kamili, Saleem ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HEPATITIS C RAPID TEST; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRE MARKET RAPID ANTI HCV ASSAY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; UNITED STATES;

HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HEPATITIS C ANTIGENS; HUMANS; REAGENT KITS, DIAGNOSTIC; SENSITIVITY AND SPECIFICITY; TIME FACTORS; UNITED STATES;

EID: 84871951538     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2470     Document Type: Review

References (36)

1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705-714.
2. CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998; 47:1-39.
3. Roblin DW, Smith BD, Weinbaum CM, Sabin ME. Hepatitis C virus screening practices and prevalence in a managed care organization, 2000-2007. Am J Manag Care 2011; 17:548-555.
4. Southern WN, Drainoni ML, Smith BD, et al. Hepatitis C testing practices and prevalence in a high-risk urban ambulatory care setting. J Viral Hepat 2011; 18:474-481.
5. Wasley A, Finelli L, Bell BP, Alter MJ. The knowledge and behavior of HCV-infected persons identified in a national seroprevalence survey, United States, 2001-2004. 12th International Symposium on Viral Hepatitis and Liver Disease. 1-5 July 2006, Paris, France. Poster 445.
6. CDC. Viral Hepatitis Surveillance United States, 2009. MMWR 2011; 58:1-27.
7. Amon JJ, Garfein RS, Ahdieh-Grant L, Armstrong GL, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, 1994-2004. Clin Infect Dis 2008; 46:1852-1858.
8. Hagan H, Pouget ER, Des Jarlais DC, Lelutiu-Weinberger C. Meta-regression of hepatitis C virus infection in relation to time since onset of illicit drug injection: the influence of time and place. Am J Epidemiol 2008; 168:1099-1109.
9. Edlin BR, Carden MR. Injection drug users: the overlooked core of the hepatitis C epidemic. Clin Infect Dis 2006; 42:673-676.
10. Thorpe LE, Ouellet LJ, Hershow R, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol 2002; 155:645-653.
11. Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 18 Suppl 1:S11-S19.
12. Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology 2001; 34:180-187.
13. Spradling PR, Richardson JT, Buchacz K, et al. Trends in hepatitis C virus infection among patients in the HIV Outpatient Study, 1996-2007. J Acquir Immune Defic Syndr 2010; 53:388-396.
14. Tempalski B, Lieb S, Cleland CM, Cooper H, Brady JE, Friedman SR. HIV prevalence rates among injection drug users in 96 large US metropolitan areas, 1992-2002. J Urban Health 2009; 86:132-154.
15. Kaplan JE, Masur H, Holmes KK. Guidelines for preventing opportunistic infections among HIV-infected persons-2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep 2002; 51:1-52.
16. Taylor LE. Delivering care to injection drug users coinfected with HIV and hepatitis C virus. Clin Infect Dis 2005; 40 Suppl 5:S355-S361.
17. Jewett A, Smith BD, Garfein RS, Cuevas-Mota J, Teshale EH, Weinbaum CM. Field-based performance of three pre-market rapid hepatitis C virus antibody assays in STAHR (Study to Assess Hepatitis C Risk) among young adults who inject drugs in San Diego, CA. J Clin Virol 2012; 54:213-217.
18. Molitor F, Bell RA, Truax SR, Ruiz JD, Sun RK. Predictors of failure to return for HIV test result and counseling by test site type. AIDS Educ Prev 1999; 11:1-13.
19. Drobnik A, Judd C, Banach D, Egger J, Konty K, Rude E. Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations. Am J Public Health 2011; 101:2151-2155.
20. Lee SR, Kardos KW, Schiff E, et al. Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid. J Virol Methods 2011; 172:27-31.
21. Lee SR, Yearwood GD, Guillon GB, et al. Evaluation of a rapid, point-of-care test device for the diagnosis of hepatitis C infection. J Clin Virol 2010; 48:15-17.
22. Smith BD, Drobeniuc J, Jewett A, et al. Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus. J Infect Dis 2011; 204:825-831.
23. Smith BD, Teshale E, Jewett A, et al. Performance of premarket rapid hepatitis C virus antibody assays in 4 national HIV behavioral surveillance system sites. Clin Infect Dis 2011; 53:780-786.
24. Alter MJ, Kuhnert WL Finelli L. Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention. MMWR Recomm Rep 2003; 52:1-13.
25. van den Berg CH, Grady BP, Schinkel J, et al. Female sex and IL28B, a synergism for spontaneous viral clearance in hepatitis C virus (HCV) seroconverters from a community-based cohort. PLoS ONE 2011; 6:e27555.
26. Kendrick SR, Kroc KA, Withum D, Rydman RJ, Branson BM, Weinstein RA. Outcomes of offering rapid point-of-care HIV testing in a sexually transmitted disease clinic. J Acquir Immune Defic Syndr 2005; 38:142-146.
27. Lubelchek R, Kroc K, Hota B, et al. The role of rapid vs conventional human immunodeficiency virus testing for inpatients: effects on quality of care. Arch Intern Med 2005; 165:1956-1960.
28. Metcalf CA, Douglas JM, Jr, Malotte CK, et al. Relative efficacy of prevention counseling with rapid and standard HIV testing: a randomized, controlled trial (RESPECT-2). Sex Transm Dis 2005; 32:130-138.
29. Greub G, Ledergerber D, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-1805.
30. Vali B, Jones RB, Sakhdari A, et al. HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression. Eur J Immunol 2010; 40:2493-2505.
31. Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002; 16:813-828.
32. Keenan PA, Keenan JM. Rapid hiv testing in urban outreach: a strategy for improving posttest counseling rates. AIDS Educ Prev 2001; 13:541-550.
33. Christopoulos KA, Kaplan B, Dowdy D, et al. Testing and linkage to care outcomes for a clinician-initiated rapid HIV testing program in an urban emergency department. AIDS Patient Care STDS 2011; 25:439-444.
34. Spielberg F, Branson BM, Goldbaum GM, et al. Choosing HIV counseling and testing strategies for outreach settings: a randomized trial. J Acquir Immune Defic Syndr 2005; 38:348-355.
35. Muerhoff AS, Jiang L, Shah DO, et al. Detection of HCV core antigen in human serum and plasma with an automated chemiluminescent immunoassay. Transfusion 2002; 42:349-356.
36. Hosseini-Moghaddam SM, Iran-Pour E, Rotstein C, et al. Hepatitis C core Ag and its clinical applicability: potential advantages and disadvantages for diagnosis and follow-up? Rev Med Virol 2012; 22:156-165.